Index

ABCE models 18
Abuja Goals Fund see AGF
AD (auto-disposable syringes) 81, 83
transmission probability 83
Addis Ababa conference see Civil Society Panel
Addis Ababa Youth Forum Prioritization 347
adolescent sexual activity 239, 241, 251–2, 254, 258, 260–1, 269–70, see also keeping girls in school
Afrobarometer project 227, 230–1, 232
age factors 20–1
AGF (Abuja Goals Fund) 6, 183, 184, 186, 201–5, 206, 222, 229–33, 344, 346, 347
AIDS
deaths averted costs 306–7
denial by politicians 234, 235
epidemiology 301
funding 342
future scenarios 304–5
R&D see vaccine research and development
retro-virus discovered 61, see also ART
trials 314–18
vaccine 7
AIDS in the Twenty-First Century: Disease and Globalisation 68
AIDS: Taking a Long-Term View 2
AIDS vaccine
accelerating development 309–12, 346, 347
access to 325
alternatives to 326
benefit-cost ratios 310, 321, 326
benefits 309
costs 305–6, 321, 322–3
in sub-Saharan Africa 306
disinhibition 146, 324–5
effectiveness 323–4
and epidemic future 324
paying for 325–6
research 330
societal benefits 321
synergistic benefits 325
aids2031 Consortium xx, 2
Modeling Working Group xix
AIDSCost projection program 128, 147
AIM (AIDS Impact Model) 78–9, 89–90, 96–7
alcohol
abuse as HIV epidemic driver 285
Laffer Curve 244
problematic use of 239, 242–5
substitution 244
Angola
alcohol tax 262–3
blood supply testing 86
HIV epidemic scale 65–6
HIV incidence/prevalence 13
key indicators 115–16
anthropometric outcomes 55
Appel, Jacob 191
ART (anti-retroviral treatment)
access to treatment 125, 140–1, 181, 185, 233–4
AIDSCost projection program 128, 147
anti-retroviral prophylaxis options 109–10, 122
at-risk groups targeting strategy 312
and behavioral responses 50–1
benefit-cost analyses
for successful infection prevention treatment 159–60
for unsuccessful infection prevention treatment 156
benefit-cost ratios 76, 77–8, 137, 138–9, 143, 145, 178–82
benefit-cost results 141–2, 146–8
best treatment stage 125–6
CD4 cells 110–12, 125–6, 127–30, 136, 137–9, 141–2, 143–4, 156, 160, 178
CD4 counts and eligibility 181
cost-effectiveness 141–2
costs 32, 77, 126–7, 145, 169, 178
coverage 128
and family planning 222
drug costs 308
and dynamics of HIV infection 103–4
eligibility guidelines 213–14
extension of 15
feedback effects 219–20
future cost per patient 178–9
historical counterfactual 135
HIV transmission models 79–81, 131–3
incremental spending 140
infections reduction incremental benefits 194
life years gained 79–81, 184
lifelong treatment 109–10, 112
mother-to-child infections 75
national uptake rate 128
Nobel Laureate Economist Expert Panel findings on 339
non-AIDS mortality rate 180
numbers treated by 1
oral 301
patient life expectancy 138–9
and prevention techniques 70
primary infection prevention 159
scaling-up benefits 181, 346, 347
scaling-up enrollment 343, 347–8
secondary infection prevention 159
simulated scenarios 135–7
spillover benefits 145
statistics provision 79
in sub-Saharan Africa xix
sufficient damage factor 127
survival years 180–1
TDF/FTC combination 54
topical 301
topical microbicides 238
treatment cost per person/year 135, 173–4
treatment criteria 128
treatment dynamics modeling 127–30
treatment eligibility 334
treatment emergence 125
treatment impact modeling 130–3, 142–5
treatment unit costs 133–5
treatment uptake rate modeling 128–30
uptake projection 139–40
value of lives saved 78
zero uptake 135, 136
and benefit-cost ratios 151
simulation results 139
adverse side effects 174
and AIDS vaccine 305
benefit-cost ratio 173
cost decline 179
deployment of 146
potential cost reduction 179
Ayeeetey, Ernest 337–8
at-risk groups targeting strategy 312
AVERT model 79–81
AZT (Zidovudine) program 162
B/C ratios, naive estimates of 155
Balbunse, Rob 5
Banerjee, Abhijit 191
Barnett, Tony 6
Bärnighausen, Till 6
BCC (behavioral change communication) 16
BCR see benefit-cost ratios
behavioral prevention programs 14–15
Behrman, Jere 4, 349
benefit estimates 103–4
benefit-cost analyses 21, 23
continued investment 308–9
DALYs (disability-adjusted life years) 20, 22, 26–9, 32–3, 34–40, 41–2, 49, 62, 226
display in World Bank 190
dynamic framework time representation 155–60
HC (Human Capital) approach 170
HIV treatment pre-pregnancy 164–6
information campaigns (IC) 25–6
and interventions 108
life-cycle perspective 26, 30, 62
Nobel Laureate Economist Expert Panel findings on 337
for policy interventions 26–32
discounting 31
estimation challenges 31–2
general considerations 26–30
interaction among solutions 31
prices 30
range of costs 31
range of impacts 30
scale 31
pregnant women 167–8
and sets of objects 283
for successful infection prevention treatment 159–60
and unrecognized metaphors 281
for unsuccessful infection prevention treatment 156
vaccine research and development 304–9
WTP (willingness to pay) 170–1
benefit-cost ratios 5, 36–7, 40–1, 181–2, 189
AIDS vaccine development 310
ART 32, 76, 77–8, 137, 138–9, 143, 145, 146–8, 178–82
and ARV provision 173
CCTs 220–2
CD4 cell count 158–60
community health 198
cross-country variations 293
discounted/undiscounted 156, 175
health system strengthening 208
HIV reduction interventions 34–7, 41–2, 63–4, 174, 293
infections averted 32
interventions 260–3
male circumcision 36–7, 40–1, 63–4, 339
pMTCT in sub-Saharan Africa 160–1, 163, 174–5
procedures summary 32–3
treatment costs 32
treatment as prevention 151
unit costs 294–5
varying average costs 294–5
VSL (Value of a Statistical Life) approach 170–1
Benin
alcohol tax 262–3
blood supply testing 86
HIV incidence/prevalence 13, 114–17
key indicators 115–16
problems faced by government (Afrobarometer) 232

© in this web service Cambridge University Press

www.cambridge.org
blockbuster drugs 303
blood safety intervention 186
blood transfusions 4, 74, 86–8, 89, 102–3, 346, 347
Bloom, David 5–6
BMGF (Bill and Melinda Gates Foundation) 213
body undergoing treatment metaphor 283–4
Bollinger, Lori 4, 102, 105, 121, 169–70, 171, 259, 347–8
Botswana
alcohol tax 262–3
health priority survey 230–1
HIV epidemic scale 65–6
HIV incidence/prevalence 12, 13, 29, 30, 34, 39–40
key indicators 115–16
life expectancy with/without AIDS 162
male circumcision 25, 40–1
problems faced by government (Afrobarometer) 232
resources allocated to 15–17
unmet need for family planning 165
Brandeau, M. L. 295
Brazil, AIDS vaccine 325
Brent, Robert 5
British Columbia Center for Excellence on HIV/AIDS 69–70
Burkina Faso
Abuja target 202
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
life expectancy with/without AIDS 162
unmet need for family planning 165
Burundi
alcohol tax 262–3
HIV incidence/prevalence 13
key indicators 115–16
life expectancy with/without AIDS 162
unmet need for family planning 165
bush circumcisions 52
Cambodia, conditional cash transfers 254
Cameroon
alcohol tax 262–3
HIV incidence/prevalence 13
key indicators 115–16
life expectancy with/without AIDS 162
unmet need for family planning 165
Campbell Collaboration 65
cancer as investment priority 189
canine distemper, and vaccine research and development 313
Cape Verde, problems faced by government (Afrobarometer) 232
CAPRISA (Centre for the AIDS Programme of Research in South Africa) 64
CAPRISA Study 54
cash incentive programs see CCT
CBA (cost-benefit analysis) see benefit-cost analyses
CCT (conditional cash transfer) 21, 23, 31, 53, 54–8, 191–3, 218
benefit-cost ratios 220–2
conceptual foundations of 56
current evidence on 57–8
female education 245
and HIV awareness 192
and HIV testing 228–9
and infection reduction 222
and joint objectives 184
keeping girls in school see keeping girls in school
potential impacts of 186
rationale for 54–7
RESPECT study 193
CD4 count 110–12, 125–6, 127–30, 136, 137–9, 141–2, 143–4, 156, 160, 172, 173, 178, 199
cell count and ART eligibility 181
cell count benefit-cost ratios 158–60
death probability 180–1
point of care dipsticks 179
screening 161
CEA see cost-effectiveness analyses
Central African Republic
alcohol tax 262–3
health worker shortage 196
HIV incidence/prevalence 13, 196
key indicators 115–16
life expectancy with/without AIDS 162
Chad
alcohol tax 262–3
HIV incidence/prevalence 13
key indicators 115–16
unmet need for family planning 165
CHAPA program 248–9
childhood diseases, as investment priority 189
Chimeric Venezuelan Equine Encephalitis 313
China, conditional cash transfers (one-child policy) 191
CHWs (community health workers) deployment 216, 218
Technical Task Force 186, 196, 197–9
training costs/benefits 220–2
circumcision see MC
Civil Society Panel 341, 349
Abuja Goals Fund 344
AIDS funding 342
ART (anti-retroviral treatment) scaled-up enrollment 343
CCT (conditional cash transfer) and keeping girls in school 343–4
keeping girls in school 343–4, see also keeping girls in school
mother-to-child transmission prevention (pMTCT) 342–3, 347–8
redefining priorities theme 341
CM (contingency management) 55–6
CMH (Commission on Macroeconomics and Health) 104, 195, 203
COD (cash on delivery)
and Abuja Goals Fund (AGF) 201–5, 206, 229–33
donor assistance 184
to governments 218
Collier, Paul 337–8
combination prevention 145
commodity approach to strategies 15
community health workers 183, 184, 206, 207, 228
community mobilization 248–9, 253, 255, 259, 265, 267,
268, 269–70, 293
Community Systems Strengthening Framework 235
Comoros
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
concurrent sexual partners, as HIV epidemic driver 285
condoms 11, 19, 51, 56, 68, 170, 248
Congo
Abuja target 202
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
life expectancy with/without AIDS 162
unmet need for family planning 165
contraception, unmet need for 164
see also condoms; family planning
Copenhagen Consensus Center, global development project (2008) 2
Copenhagen Consensus Challenge paper 245
Copenhagen Consensus project (2004) 2
cost-effectiveness xx, 11, 17–23, 37–9, 49, 58
blood transfusions 74, 86–8
ICER (incremental cost-effectiveness ratio) 75–6
injecting drug users 92–5
interventions 17–23, 242–5, 260
medical injections 74, 81–6
mother-to-child transmission 74, 121
in sub-Saharan Africa 11, 20, 104
cost-effectiveness analyses 22, 283
and unrecognized metaphors 281
cost estimates 103
cost per death 194, 198
cost per infection 104
Cote d’Ivoire
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
key indicators 115–16
life expectancy with/without AIDS 162
OIs (opportunistic infections) 76–7, 78
unmet need for family planning 165
cotrimoxazole prophylaxis 161
couple-based HIV testing 20
CRAG (cryptococcal antigen) costs and benefits 186, 200–1, 208
testing 199–200, 201, 228
critical enablers 188–9
cross-intervention benefits 347
cryptococcal meningitis (CM) 183, 200–1, 206, 216, 218,
220, 340
Cryptococcosis neoformans 184, 199–201
cultural practices, as HIV epidemic driver 285
Cytomegalovirus Clinical Development Program 313
DALYs (disability-adjusted life years) 20, 22, 26–9, 34–40,
41–2, 49, 62, 63–4, 75–6, 104, 170–1, 175–6,
189–90, 197, 200, 203, 205, 206, 207, 226, 243,
260, 263–5, 349
by country 271–2
incremental cost 274–5
parameters 260–1
DCP2 190–1
de Walque, Damien 4
death metaphors 282
deaths averted 188–9, 194, 202, 203, 204, 306–7, 308
DemProj software tool 78
diagnostic tests 300
discounting 171–2, 173, 175, 189–90, 200, 263, 333
disinhibition 146, 324–5, 339
Djibouti
Abuja target 202
key indicators 115–16
DMPTT see Male Circumcision: Decision Makers’ Program Planning Tool
donor support flat-lining 213–14
dose-response 284
drug costs 126–7, 308
drug development 300
drug supply systems intervention 186
drug users, injecting 92–5
Duflo, Esther 191
Earth Institute Technical Taskforce 195
ecology of risk 285, 286
The Economist, end of AIDS? 12
Efavirenz 111, 126
effectiveness estimates 103–4
efficiency solution 188
embodiment of social conditions 287–8
emergency rescue intervention 186
epidemic model 295
EPP (Estimation and Projection Package) 78
Equatorial Guinea
alcohol tax 262–3
HIV incidence/prevalence 13
key indicators 115–16
Eritrea
alcohol tax 262–3
HIV incidence/prevalence 13, 114–17
infant mortality 204
key indicators 115–16
life expectancy with/without AIDS 162
Ethiopia
alcohol tax 262–3
HIV prevalence 12, 114–17, 296–7
Ethiopia (cont.)
  key indicators 115–16
  life expectancy with/without AIDS 162
  life insurance incentivization 296–7
  Millennium Village Project (MVP) 247
  PEPFAR-funded interventions 255
  unmet need for family planning 165
  Voices of the Poor project 196
  evidence-based allocation strategy 17–18
  external validity of interventions 294
  faith-based abstinence 68
  family planning 97, 117, 161, 163–4, 197, 198, 202, 222
  cost-effectiveness of 164, 198–9
  social benefits 164
  unmet need for in sub-Saharan Africa 165
  Farm Input Subsidy Programme 247
  FDA, and microbicidal 64
  FEM-PrEP trial 54
  female education 245
  female sex workers 296–7
  FFS (Farmer Field School) 247, 252
  first-line treatment benefits/costs 157
  flat-lining donor support 213–14
  Forsythe, Stephen 7
  funding 1
  alternative use for 214–15
  competing demands 213–14
  G8 (Gleneagles 2005) 185
  Gabon
  alcohol tax 262–3
  HIV incidence/prevalence 13
  key indicators 115–16
  life expectancy with/without AIDS 162
  Gambia
  alcohol tax 262–3
  HIV incidence/prevalence 13
  key indicators 115–16
  Gardasil 322, 323, 325
  GAVI Alliance 184–6
  gender inequalities, as HIV epidemic driver 285
  gender role perceptions/training 239, 241, 245, 252–4, 258, 260–1, 267, 268, 269–70, 284, 343–4
  Gleneagles Summit (2006) 125
  Global Crises, Global Solutions 184–5, 190
  Global Fund Forum 342
  Global Fund-hosted Event Prioritization 346
  global political commitment, to fighting HIV 213
  Global Programme on AIDS 283
  GNI per capita statistical life value 189–90
  goal-directed thinking 288
  Goals and Allocation by Cost-Effectiveness (ABCE) models 18
  Goals Model/Goals Express 79–81, 93, 96–7, 259, 265
  going upstream metaphor 282–3
  Granich, Reuben M. 69–70, 191–2
  GS (general structure) interventions 216–18, 221
  Guinea
  alcohol tax 262–3
  HIV incidence/prevalence 13, 114–17
  key indicators 115–16
  Guinea-Bissau
  alcohol tax 262–3
  HIV incidence/prevalence 13
  key indicators 115–16
  life expectancy with/without AIDS 162
  Gupta, Geeta Rao 286
  Halperin, D. T. 19
  HCT see HTC
  health benefits, advances in estimating 190–1
  health care costs, and HIV prevention 307
  health care reform, political legitimacy of 231–3
  health center upgrade/construction intervention 186
  health inequalities and environments 287
  health priority survey 230–1
  health services strengthening, in rural areas 196–7
  health services upgrade 195–9
  health spending ratios 187
  health system capacity 226–8
  health system infrastructure and pMTCT 117–18
  health system intervention evaluation 215–17
  benefits evaluation 216–17
  costs 217
  feasibility 215
  flexibility 215
  intervention level/scope 216
technical efficiency 215

time lags/certainty levels 217–18

health system strengthening 213–23, 226–36

access improvement 228

benefit evaluation 216–18

challenges

cost-benefit ratio 208

cost evaluation 217–18

feasibility 215

flexibility 215

intervention evaluation 215–16, 217

intervention scope 216

life year value monetization 226

methodological issues 226–33

Nobel Laureate Economist Expert Panel findings on 340

structures 214–15

health workers

shortage 196

skills upgrade 195–9

staff expansion 197–9

heart attacks, as investment priority 189

Hecht, Robert 7

herpes

as epidemic driver 285

and Stepping Stones 246

heterosexual HIV transmission 303

HIA (HIV infection averted) 63–4

high-risk groups 153, 155

HIPC (highly indebted poor countries) initiative 202–3

historical counterfactual 135

HIV

and alcohol consumption 242

in couples 126, 159

deaths statistics xix, 153, 299

dynamic models of effect on 152–5

epidemic drivers 285

epidemic scale 65–6

fatality rate 125

global political commitment to fighting 213

hope and social intervention 288–90

impact modeling 255–9

incidence (of infection) 131

incidence/prevalence ratio 146–8, 213, 226–8

infections averted 255–9, 271–2

modes of transmission 66–7

POC (point-of-care) diagnostic tests 119–21

in women in sub-Saharan Africa 172–3

see also vaccine research and development

HIV counseling, universal 183

HIV information, universal 183

HIV prevention, as investment priority 189

HIV programs, demand side 218

HIV testing

monetization 229

universal 183, 228–9

HIV transmission

heterosexual 303

time lags/certainty levels 217–18

health system strengthening 213–23, 226–36

access improvement 228

benefit evaluation 216–18

challenges

cost-benefit ratio 208

cost evaluation 217–18

feasibility 215

flexibility 215

intervention evaluation 215–16, 217

intervention scope 216

life year value monetization 226

methodological issues 226–33

Nobel Laureate Economist Expert Panel findings on 340

structures 214–15

health workers

shortage 196

skills upgrade 195–9

staff expansion 197–9

heart attacks, as investment priority 189

Hecht, Robert 7

herpes

as epidemic driver 285

and Stepping Stones 246

heterosexual HIV transmission 303

HIA (HIV infection averted) 63–4

high-risk groups 153, 155

HIPC (highly indebted poor countries) initiative 202–3

historical counterfactual 135

HIV

and alcohol consumption 242

in couples 126, 159

deaths statistics xix, 153, 299

dynamic models of effect on 152–5

epidemic drivers 285

epidemic scale 65–6

fatality rate 125

global political commitment to fighting 213

hope and social intervention 288–90

impact modeling 255–9

incidence (of infection) 131

incidence/prevalence ratio 146–8, 213, 226–8

infections averted 255–9, 271–2

modes of transmission 66–7

POC (point-of-care) diagnostic tests 119–21

in women in sub-Saharan Africa 172–3

see also vaccine research and development

HIV counseling, universal 183

HIV information, universal 183

HIV prevention, as investment priority 189

HIV programs, demand side 218

HIV testing

monetization 229

universal 183, 228–9

HIV transmission

heterosexual 303

models 79–81, 131–3

rate estimation 151

in sub-Saharan Africa 238

sustainability and income inequality 287

HIV treatment

for all women 164–6

benefits of prevention 306–8

costs 70

efficiency 215

immediacy 70

individual effects 70

population effects 70

programs’ integration with primary health care 214–15

selective expansion 214–15

selective integration 214–15

stand-alone programs 215

see also ART (anti-retroviral treatment); HSS (health system strengthening)

HIV vulnerability, social drivers 239

HIV-infected children, survival rate 77

HIV/AIDS

disease statistics 200

R&D see vaccine research and development

social policy interventions 281–90

spending and health systems strengthening 186–7

HIVNS (HIV-focused non-structural) interventions 216–18, 221

HLT (High Level Taskforce on International Innovative Financing for Health Systems) 185, 195, 202–3

Hontelez, Jan 5

hope

analytical advantages 289

as diagnostic tool 289–90

and income 289

and optimism 288

and palliative care 289

and social intervention 288–90

HSS (health systems strengthening) 184, 186–7, 204–5

expansion of 214–15

and health worker skills upgrade 195–9

intervention scale 219

interventions implementation time 219

potential of 215

priority setting 220

targeting vulnerable populations 220

unintended consequences 218–19

HTC (HIV testing and counseling) 14–15, 19–20, 22–3, 25, 41–2

benefits of 49–50, 62–3

and Civil Society Panel 344

cost-benefit ratio 63–4

cost-effectiveness 37

costs of 33–4

and HIV incidence 33–4

as prevention 69–70, 192–3

treatment as prevention 166–8

uptake at community level 248
Humair, Sal 6
human resources training intervention 186
human rights and conditional cash transfers 191
hyperbolic discounting 190

IAVI (International AIDS Vaccine Initiative) 299, 305–6
research developments source 313
IC (information campaigns) 20, 25–6, 34, 41–2, 49–50, 52–3, 62, 63–4, 70–1
ICASA 341, 346
ICD (infectious and communicable diseases) 188
ICER (incremental cost-effectiveness ratio) 75–6
IDU (injecting drug use) interventions 92–5, 96, 102–3, 104, 105
IeDEA Consortium 180
IHP+ (International Health Partnerships) 184–5, 195, 202–3, 204–5
IMAGE (Intervention with Microfinance for AIDS and Gender Equity) 21, 246, 247, 252, 254–5, 258–9
immunodeficiency virus 20–1
impact evaluations 50
inappropriate metaphors 281–8
income inequality and poverty/transmission susceptibility 287
incremental benefits 194
incremental spending results 140
India, conditional cash transfers (vasectomy grants) 191
individual behavior
environment as regulator of 286–7
and risk environments 286
infant HIV exposure diagnosis 161
infant infections 188, 198
infant lives saved 207
infant mortality 203, 204
infants, as most valued lives 190
infection probability model 79–81
information technology intervention 186
initiation schools 52
injecting drug users 75, 92–5
Institute for Health Metrics and Evaluation 332
intergenerational sexual behavior as HIV epidemic driver 285
intergenerational transmission of disease 33, 285
International Conference on AIDS (ICASA) 341, 346
International Group on Analysis of Trends in HIV Prevalence and Behaviors in Young People in Countries most Affected by HIV (2010) 19
International HIV/AIDS Alliance 248–9
interventions
adolescent sexual activity 239, 241, 245, 247, see also keeping girls in school
AGF (Abuja Goals Fund) see AGF
alcohol problematic use of 239, 242–5
taxation see alcohol taxation
anthropometric outcomes 55
beneficiaries of 105
benefit-cost ratios 260–3
and CBA (cost-benefit analysis) 108, 242–5
CCT (conditional cash transfer) see CCT (conditional cash transfer)
community mobilization see community mobilization
cost-effectiveness 17–23, 242–5, 260
criteria for 61–2
cross-intervention benefits 347
demand-side 55, 245
effectiveness 17–23, 242–5
evidence-based allocation strategy 17–18
external validity of 294
gender role perceptions/training see gender roles
perception/training
GS (general structure) 216–18
HIV infection reduction 34–9, 255–9
HIV reduction benefit-cost ratios 34–7, 41–2, 63–4, 174
HIV treatment issues 70
and HIV vulnerability social drivers 239
HAVNIS (HIV-focused non-structural) 216–18, 221
and hope 288–90
HSS (health systems strengthening) and cost-benefit analyses 221
objectives 186
scale 219
IDU 92–5
IMAGE see IMAGE
impact evaluations 50
implementation time 219
investment priorities 189
keeping girls in school see keeping girls in school
local diagnosis 289
location-specific 15–17
long-lasting 222
and MSM 53
Nobel Laureate Economist Expert Panel findings 337–8
and orphan care costs 311
pMTCT (mother-to-child transmission) 109–13, 118, 121, 151, 160–6
and population size 17
potential behavioral responses 50–2
potential beneficiaries 39–41
pre-exposure chemoprophylaxis 53, 54
preventative vs treatment 104–5
prevention efficiency 52–3
priority setting 220
sexually transmitted infections 50
Stepping Stones 246, 258–9
stigma of HIV/AIDS 1, 4, 6, 20, 97, 238, 239, 240, 242, 255, 265
structural interventions 286
target populations 220, 247, 248–9
targeted approaches 53
and technologies/strategies 329
total costs per country 272–3
transferable social policy 283–4

© in this web service Cambridge University Press  www.cambridge.org
trusted interventions 19
unit costs per country 272–3
vulnerable populations 220
investment approach to strategies 15, 17, 21
six program components 15
iPrEx study 54
IPV (intimate partner violence) 265
irresponsible sexual behavior as HIV epidemic driver 285
Jamison, Dean 7, 189
Johri, Mira 5
Kazianga, Harounan 6–7
keeping girls in school 245, 251–2, 254, 258, 260–1, 267, 268, 269–70, 284, 293, 294, 343–4, 346, 347
Kemron 51
Kenya
alcohol tax 262–3
alcohol taxation 244
ART cures 51
development indicators 227
family planning unmet needs 165
health priority survey 230–1
HIV epidemic scale 65–6
HIV incidence/prevalence 12, 13, 66–7, 296–7
IDU (injecting drug use) interventions 92–5, 96–7
key indicators 115–16
life expectancy with/without AIDS 162
life insurance incentivization 296–7
life-year costs 145
life-year values 137, 164, 170–1, 188–9
monetization 226
life-years gained 179–81, 188, 200, 307
LiST software tool 78
location-specific interventions 15–17
LoveLife campaign 70
McGreevey, William 5–6
Madagascar
alcohol tax 262–3
health priority survey 230–1
HIV incidence/prevalence 13
key indicators 115–16
problems faced by government (Afrobarometer) 232
Makhwapheni Campaign 70–1
Making Services Work for Poor People 233
malaria, as investment priority 189
Malawi
alcohol tax 262–3
cash incentive programs 21, 57–8
CCTs (conditional cash transfers) 192–3, 245
development indicators 227
donor money corruption 231
family planning 197
Farm Input Subsidy Programme 247
GNI per capita 226–8
health priority survey 230–1
health workers 196, 228
HIV epidemic scale 65–6
HIV incidence/prevalence 13, 34, 196
HIV and sexual contact 14
key indicators 115–16
life expectancy 226–8
with/without AIDS 162
male circumcision 23–5
Millennium Village Project (MVP) 247
needle-sharing infections 74
problems faced by government (Afrobarometer) 232
sexually transmitted HIV 11
unmet need for family planning 165
liability and cost ratio 323
Liberia
Abuja target 202
alcohol tax 262–3
HIV incidence/prevalence 13
key indicators 115–16
life expectancy with/without AIDS 162
life expectancy 161, 169
life insurance 6–7
incentivization 296–7
life-cycle perspective 26, 30, 62
life-year costs 145
life-year values 137, 164, 170–1, 188–9
monetization 226
life-years gained 179–81, 188, 200, 307
LiST software tool 78
location-specific interventions 15–17
LoveLife campaign 70
Malawi
alcohol tax 262–3
cash incentive programs 21, 57–8
CCTs (conditional cash transfers) 192–3, 245
development indicators 227
donor money corruption 231
family planning 197
Farm Input Subsidy Programme 247
GNI per capita 226–8
health priority survey 230–1
health workers 196, 228
HIV epidemic scale 65–6
HIV incidence/prevalence 13, 34, 196
HIV and sexual contact 14
key indicators 115–16
life expectancy 226–8
with/without AIDS 162
male circumcision 23–5
Millennium Village Project (MVP) 247
PBI (performance-based incentive) 192
problems faced by government (Afrobarometer) 232
SIHR (Schooling, Income, and HIV Risk) study 193
unmet need for family planning 165
Voices of the Poor project 196
male circumcision see MC
Mali
- alcohol tax 262–3
- HIV incidence/prevalence 13, 114–17
- key indicators 115–16
- problems faced by government (Afrobarometer) 232
- mass media IC (information campaigns) 25–6, 34, 41–2, 49–50, 52–3, 62, 63, 70–1
- maternal health and child survival 111
- maternal mortality 197, 198, 202

Mauritania
- HIV incidence/prevalence 13, 114–17
- key indicators 115–16

Mauritius
- alcohol tax 262–3
- HIV incidence/prevalence 13, 114–17
- IDU (injecting drug use) infection 92–5
- key indicators 115–16

MBB (marginal budgeting for bottlenecks) 185, 203

MBeki, President Thabo 234, 235

MC (male circumcision) 4, 12, 15, 18, 21, 22–5, 41–2, 49–50, 300, 301, 346
- benefit-cost ratios 36–7, 40–1, 63–4, 339
- bush circumcisions 52
- cost-effectiveness of 58, 62
- costs of 33
- as high priority 348
- infant 339, 348
- and infection prevention 326
- intervention efficiency 52–3
- intervention requirements 39–41
- key issues 69
- lack of as HIV epidemic driver 285
- long-term benefits 25–6, 62, 66, 68–9
- Male Circumcision: Decision Makers’ Program Planning Tool (DMPPT) 18
- neonatal 25, 52
- uptake and resources 323

MDGs see Millennium Development Goals

Medecins Sans Frontiers 159

medical injections 4, 74, 81–5, 86, 102–3

medical male circumcision see MC

Mema wa Vijana intervention 255

men who have sex with men see MSM

Menberu, Retta 341, 343, 345

Merck vaccine failure 302

metaphorical language in social policy interventions 281–90

metaphors
- and cost-effective analyses 281
- inappropriate 281–8
- risk behavior 284–6
- structural drivers 284–6
- unexamined 281–6
- unrecognized 281

Mexico, conditional cash transfers 191, 254

microbicides and HIV risk 64, 71

microfinance schemes 21, 246, 247

Millennium Development Goals
- failure to achieve 341
- Goal 4 (reduce child mortality) 121–2
- Goal 5 (improve maternal health) 121–2
- Goal 6 (combat HIV/AIDS) 121–2, 242

Millennium Village Project (MVP) 247, 252

Mills, Anne 185

Mix Market platform 252

modes of transmission 66–7

Montaner, J. S. G. 69–70

moral hazard 146

More than good intentions 191

most-valued persons 189–90

MOT (Modes of Transmission) model 81, 102, 103–4

mother-to-child transmission 4, 5, 74, 75, 77, 88–92, 160–6

anti-retroviral prophylaxis options 109–10, 121

AP (assessment paper) analysis 107, 108, 110–12

CBA (cost-benefit analysis) 108

CD4 screening 161

contraception 164

family planning 117, 161, 163–4

cost-effectiveness of 164

infant HIV exposure diagnosis 161

labor ward screening 118–19

maternal health and child survival 111

maternal mortality 197

multiple POC (point-of-care) diagnostic tests 119

non-health facility births 119

pMTCT cascade 107, 117, 118, 122

potential HIV rates in sub-Saharan Africa 163


analytic timeframe 111–12

benefit-cost reduction 174–5, 342–3

CD4 cell count 110–12, 172

and Civil Society Panel 342–3

comprehensive vs narrow approach to 108–9

costs
- and health system infrastructure 113
- and HIV prevalence 113
- emerging technology 122
- forward transmission impact 107, 112
- full benefits definition 161
- and health system infrastructure 117–18
- intervention options 109–12, 113, 151
- key challenges 113–18

Nobel Laureate Economist Expert Panel findings 342–3

pre-pregnancy 164–6

scaling up 346, 347

services increase requirements 121–2

solutions 118–21

therapeutic options 111, 112, 121

treatment evaluation 172

treatment targets 156

treatment vs family planning 163–4

primary prevention 164
screening tests 161
in sub-Saharan Africa 74, 107, 163
testing and counseling 161
WHO Option A strategies 107–8
Mozambique
alcohol tax 262–3
development indicators 227
health worker shortage 196
HIV epidemic scale 65–6
HIV incidence/prevalence 13, 34, 39–40, 196
key indicators 115–16
life expectancy with/without AIDS 162
male circumcision 40–1
problems faced by government (Afrobarometer) 232
unmet need for family planning 165
MSM (men who have sex with men) 4, 53, 66–7, 69, 238
MTCT see mother-to-child transmission
multiple partners 126, 159
multiplex POC (point-of-care) diagnostic tests 119–21
Namibia
alcohol tax 262–3
health priority survey 230–1
HIV incidence/prevalence 13, 34
key indicators 115–16
life expectancy with/without AIDS 162
male circumcision 23–5
problems faced by government (Afrobarometer) 232
unmet need for family planning 165
NAT (nucleic acid amplification testing) 86
national epidemics 283
national strategies xx
National Technical Teams (NTTs) 345
NaTrass, Nicoli 6
needle-exchange 105
neonatal circumcision 25, 52
Nevaprine 126, 161–2
Niger
alcohol tax 262–3
blood supply testing 86
HIV incidence/prevalence 13, 114–17
key indicators 115–16
Nigeria
alcohol tax 262–3
development indicators 227
health system capacity 226–8
HIV epidemic scale 65–6
HIV incidence/prevalence 13
key indicators 115–16
life expectancy with/without AIDS 162
problems faced by government (Afrobarometer) 232
unmet need for family planning 165
Nobel Laureate Economist Expert Panel 337–8
non-sexual HIV transmission prevention
AIDS impact model 78–9
analysis methods 102, 103–4
benefits calculation 76–8
benefits summary 96
blood transfusions 74, 86–8, 102–3
Goals Model/Goals Express 79–81
HIV infections averted model 78
injecting drug users 92–5
medical injections 4, 74, 81–5, 86, 102–3
mother-to-child transmission 4, 5, 74, 88–92, 169–70
multi-country analysis options/limitations 102–3
recommendations 96–7
resource allocation equity 105
NVP (Nevirapine) program 126, 161–2
Ok&G model of infections 152–3
and high-risk groups 155
infection flows 155
with interventions 153–4
transmission mechanism specification 154–5
Odumbe, Ken 341, 342, 345
OIs (opportunistic infections) 76–7, 78, 89, 307, 311
One Million Community Health Workers 195
operations research intervention 186
opioid substitute therapies 105
oppression illness 287
oral anti-retrovirals 301
oral prophylaxis 238
orphan care costs 311
OST (opioid substitution therapy) 75, 105
Padian, N. S. 2
patient transport intervention 186
PBI (performance-based incentive) 192
Pearl Omega 51
Peer Group IC (information campaigns) 25–6, 34, 41–2, 49–50, 52–3, 62, 63
pilot studies, external validity of 294
Piot, Peter xx
Platform for Health System Strengthening 195
pMTCT see mother-to-child transmission
POC (point-of-care) diagnostic tests 119–21
Poor Economics, a Radical Rethinking of the Way to Fight Global Poverty 191
poverty as HIV epidemic driver 285, 287
pre-exposure prophylaxis 154, 301
chemoprophylaxis 53, 54, 58
Prescott, Edward C. 337–8
preventative interventions 104–5
Prevention of Non-sexual Transmission Assessment Paper 169–70
primary health care, HIV treatment integration with 214–15
primary infection prevention 159
production function model 295
promiscuous sexual behavior as HIV epidemic driver

Protocol G

QALYs (quality-adjusted life years)

RAPID software tool

Rasmussen, Prime Minister Anders Fogh

RBF (results-based financing)

RCTs (randomized controlled trials)

hope and intervention studies

role of 64–5

and spillover benefits

Remme, Michelle

research intervention

RESPECT study 57, 193

RethinkHIV project

Roth Foundation

Rwanda

Abuja target 202

alcohol tax 262–3

HIV awareness

HIV incidence/prevalence 13

key indicators 115–16

problems faced by government (Afrobarometer) 232

sexual abstinence 68, 255

sexual abstinence month 4, 71

sexual behavior, different contexts 283

sexual health, and CM (contingency management) 55–6

sexual infections 11, 41–2, 49

sexual practices, cultural 285

sexual relations

frequency 193

and HIV prevention 11–17, 20, 33, 34–7, 41–2

risk-taking behavior 56–7

see also keeping girls in school

sexually transmitted diseases (STDs)

and alcohol 243

HIV 11, 18, 32, 50–2, 63–4, 66–7, 74, 169–70, 238, 300, 339

prevention basics 67–8

see also non-sexual HIV transmission

sexually transmitted infections (STIs) 11, 41–2, 49, 50, 65, 300, 339

as HIV epidemic drivers 285

Sierra Leone

alcohol tax 262–3

HIV incidence/prevalence 13

key indicators 115–16

SIHR (Schooling, Income, and HIV Risk) study 193

simulated scenarios in ART (anti-retroviral treatment) 135–7

Smith, Vernon L.

Snyder, Richard

social conditions, embodiment of 287–8

social intervention, and hope 288–90

social policy interventions 281–90

Nobel Laureate Economist Expert Panel findings on 339–40

Somalia, key indicators 115–16

Somaliland, Voices of the Poor project 196

South Africa

alcohol tax 262–3

alcohol taxation 243

ART program 217

development indicators 227

GNI per capita 226–8

health system capacity 226–8

HIV epidemic scale 65–6

HIV incidence/prevalence 12, 13

HIV testing 195

HIV/AIDS disease statistics 200

HIV/AIDS stigma 248–9

IDU (injecting drug use) intervention 92–5, 96–7

IMAGE (Intervention with Microfinance for AIDS and Gender Equity) 21, 246, 247

key indicators 115–16

life expectancy 226–8

with/without AIDS 162

male circumcision 23–5

S-I (susceptible-infection) transmission system 152–5

safe blood transfusions see blood transfusions

safe medical injections 81–6

precautions intervention 186

Salomon, Joshua 7

Schelling, Thomas C. 337–8

schistosomiasis 97

schoolgirls see keeping girls in school

secondary infection prevention 159, 311

Sendai virus 313

Senegal

alcohol tax 262–3

HIV incidence/prevalence 13, 114–17

key indicators 115–16

problems faced by government (Afrobarometer) 232

sexual abstinence 68, 255

sexual abstinence month 4, 71

sexual behavior, different contexts 283

sexual health, and CM (contingency management) 55–6

sexual infections 11, 41–2, 49

sexual practices, cultural 285

sexual relations

frequency 193

and HIV prevention 11–17, 20, 33, 34–7, 41–2

risk-taking behavior 56–7

see also keeping girls in school

sexually transmitted diseases (STDs)

and alcohol 243

HIV 11, 18, 32, 50–2, 63–4, 66–7, 74, 169–70, 238, 300, 339

prevention basics 67–8

see also non-sexual HIV transmission

sexually transmitted infections (STIs) 11, 41–2, 49, 50, 65, 300, 339

as HIV epidemic drivers 285

Sierra Leone

alcohol tax 262–3

HIV incidence/prevalence 13

key indicators 115–16

SIHR (Schooling, Income, and HIV Risk) study 193

simulated scenarios in ART (anti-retroviral treatment) 135–7

Smith, Vernon L.

Snyder, Richard

social conditions, embodiment of 287–8

social intervention, and hope 288–90

social policy interventions 281–90

Nobel Laureate Economist Expert Panel findings on 339–40

Somalia, key indicators 115–16

Somaliland, Voices of the Poor project 196

South Africa

alcohol tax 262–3

alcohol taxation 243

ART program 217

development indicators 227

GNI per capita 226–8

health system capacity 226–8

HIV epidemic scale 65–6

HIV incidence/prevalence 12, 13

HIV testing 195

HIV/AIDS disease statistics 200

HIV/AIDS stigma 248–9

IDU (injecting drug use) intervention 92–5, 96–7

IMAGE (Intervention with Microfinance for AIDS and Gender Equity) 21, 246, 247

key indicators 115–16

life expectancy 226–8

with/without AIDS 162

male circumcision 23–5
Index 361

Medecins Sans Frontiers project 159
microfinance schemes 247
PEPFAR-funded interventions 255
problematic alcohol use 242
problems faced by government (Afrobarometer) 232
TAC (Treatment Action Campaign) 234–5
unmet need for family planning 165
voluntary HIV testing and counseling uptake at community level 248
Spectrum policy models 78–9, 89–10, 93, 96–7, 102, 103–4
spillover benefits 145
SROH (Social Return on Investment) 248–9
SSA see sub-Saharan Africa
stand-alone HIV programs 215
standard dynamic model of infections 152
with interventions 153–4
statistical life value 189–90
Stavudine 126, 174
STIDs see sexually transmitted diseases
Stein, Zena 64
Steinberg, Jonny 234
Stepping Stones 246, 258–9
stigma of HIV/AIDS 1, 4, 6, 20, 97, 238, 239, 240, 242, 248–9, 255, 265
STIs (sexually transmitted infections) 50, 65, 66–7
Stover, John 5
strategies 329
Strengthening Health Systems 5–6
stressors 284
structural drivers metaphor 284–6
structural interventions 286, 287
sub-Saharan Africa
Abuja Goals Fund (AGF) see AGF
age-specific survival 29, 30
AIDS funding 342
AIDS incidence 12, 19, 29, 30, 34, 39–41, 181, 238
AIDS transmission models 79–81, 131–3
HIV/AIDS disease statistics 200
HIV/AIDS social policy interventions 281–90
HIV/AIDS solutions 41–2
HTC, home-based 25
ICD (infectious and communicable diseases) 188
incentivizing adults 296–7
income per capita 306
increased health spending 188
infant infections 198
infections and injections 83
interventions see interventions keeping girls in school see keeping girls in school
deployment 183
key indicators 115–16
labor ward screening 118–19
life expectancy 162, 184
life-year values 137
male circumcision 12, 23–5, 62
maternal mortality 197, 198
modes of transmission 66–7
mother-to-child transmission 74, 107
Nobel Laureate Economist Expert Panel findings 337–8
OIs (opportunistic infections) 76–7, 78
pMTCT benefit-cost ratios 160–1
pMTCT options 112–13
pMTCT services increase requirements 121–2
potential beneficiaries of intervention 39–41
potential HIV rates 163
pre-exposure chemoprophylaxis 53, 54, 58
RethinkHIV project 11
safe blood transfusions 86–8
screening tests 161
sexual relations and HIV prevention 11–17
sexually transmitted HIV 11
Strengthening Health Systems 5–6
testing and counseling 161
treatment cost per person/year 135
UNAIDS spending proposal 205
universal testing, informing, and counseling 183
unmet need for family planning 165
women and HIV 172–3
substance abuse, as HIV epidemic driver 285
Sudan, unmet need for family planning 165
supply chain management 323
Swaziland
alcohol tax 262–3
ARV requirement 174
blood transfusion infections 74
HIV epidemic scale 65–6
HIV incidence/prevalence 12, 13, 29, 30, 34, 66–7, 114–17
key indicators 115–16
life expectancy with/without AIDS 162
male circumcision 23–5
resources allocated to 15–17
sexually transmitted HIV 11
unmet need for family planning 165
unsafe medical injections 74
synergies with development sectors 188–9

TAC (Treatment Action Campaign) 234–5

Tanzania
Abuja target 202
alcohol taxation 244, 262–3, 296
blood supply testing 86
cash incentive programs 57–8
CCTs (conditional cash transfers) 245, 296
condoms 170
cost-effectiveness of HIV prevention 5, 73
development indicators 227
HIV epidemic scale 65–6
HIV incidence/prevalence 13, 283
HIV/AIDS stigma 248–9
IDU (injecting drug use) intervention 92–5, 96–7
intervention studies 170–1
key indicators 115–16
life expectancy with/without AIDS 162
life insurance incentivization 296–7
listed HIV epidemic drivers 285
Mema kwa Vijana intervention 255
problems faced by government (Afrobarometer) 232
RESPECT study 193
sexually transmitted infections 50
unmet need for family planning 165
voluntary HIV testing and counseling uptake at community level 248
VSL (Value of a Statistical Life) approach 170–1

Tanzanian AIDS Commission 285

Tanzanian epidemic 283
targeting strategy 312
TASO (AIDS Support Organization) 234–5

key indicators 115–16
life expectancy with/without AIDS 162
topical anti-retrovirals 301
topical microbicides 238
transferable social policy interventions 283–4
transmission susceptibility and income inequality 287
Treatment 2.0 Initiative 5, 174, 179
treatment interventions 104–5
treatment as prevention 166–8, 171–2
treatment resources vs stated goals 213–14
treatment unit costs 133–5
TRIPS (Trade-Related Intellectual Property Rights) agreements 168

Tshabalala-Msimang, Manto 234

tuberculosis as investment priority 189

Uganda
and Abuja Goals Fund (AGF) 207
alcohol tax 262–3
blood transfusion infections 74
CCTs (conditional cash transfers) 245
development indicators 227
HIV in couples 126
HIV epidemic scale 65–6
HIV incidence/prevalence 13, 66–7, 81, 324
HIV/AIDS stigma 248–9
infection age 307
interventions, local diagnosis of 289
key indicators 115–16
life expectancy with/without AIDS 162
Masaka intervention 255
microfinance schemes 247
OIs (opportunistic infections) 76–7, 78
PEPFAR-funded interventions 255
problems faced by government (Afrobarometer) 232
sexually transmitted HIV 11
sexually transmitted infections 50
TASO (AIDS Support Organization) 234–5
unmet need for family planning 165
UNAIDS 185–6, 188–9, 205, 235–6, 346
cost of saving life 205–6
founding of 61
improved investment approach 194–5
International Group on Analysis of Trends in HIV Prevalence and Behaviors in Young People in Countries most Affected by HIV (2010) 19
investment returns 188
and male circumcision 62
modes of transmission 66–7
program enablers 194–5
UNAIDS Global Plan 90
UNAIDS Investment Framework analysis 90
UNAIDS MOT (Modes of Transmission) model 81
UNAIDS (United Nations Joint Programme on HIV/AIDS) 108–9
UNDP (Joint United Nations Programme on HIV/AIDS) 346
unexamined metaphors 281–6
UNGASS 189
unintended pregnancies 197
unit costs per country 272–3
United Nations
General Assembly Political Declaration on HIV/AIDS xix, 74
Security Council Resolution on HIV/AIDS xix
United Nations High-Level Meeting on AIDS, Thematic Panel Discussion 214
United Nations Non-Communicable Disease Summit (2011) 61
United States, HIV prevalence 153
universal HIV testing 183, 191–2, 206
adults 193
universal precautions intervention 186
vaccine research and development 7, 299–312, 321–7
accomplishments to date 300–1
annual investment in 303–5, 321
anti-retroviral therapy 330
benefit-cost analysis 304–9
of accelerating 309–12
continued investment 308–9
benefit-cost ratios 330
demand creation costs 323
development history 302–4
funding sources 300
infections averted benefits 308
investment priorities 328–9
new technologies 328–9
investments 334
Nobel Laureate Economist Expert Panel findings on 337–9
operational protocols 302
and productivity levels 311
prospects 302–4
R&D 300–4
research agenda 301–2
research developments source 313
secondary infection prevention 311
and social value 330
spending 300
varying average costs 294–5
Vassall, Anna 6
VCT (voluntary counseling and testing) see HTC
Vesicular Stomatitis Virus 313
viral load
and HIV risk 126, 151
monitoring 179
Voices of the Poor project 196
VSL (Value of Statistical Life) approach 170–1
Watts, Charlotte 6
Whiteside, Alan 4
WHO (World Health Organization)
on alcohol taxation 243
Options 5, 162–3
program 162
women living with HIV, unintended pregnancies 197
World Bank
decline in benefit-cost analysis 190
health funding evaluation 233, 235–6
results-based funding (RBF) programs 202–3
structural adjustment lending 231–3
Voices of the Poor 196
World Development Report 1993, Investing in Health 203
WTP (willingness to pay) 170–1
ZAC (Zanzibar AIDS Commission) 283
Zambia
Abuja target 202
alcohol tax 262–3
development indicators 153
health priority survey 230–1
health worker shortage 196
HIV epidemic scale 65–6
HIV incidence/prevalence 12, 13, 19, 34, 66–7, 196
key indicators 115–16
life expectancy with/without AIDS 162
life insurance incentivization 296–7
male circumcision 23–5
OIs (opportunistic infections) 76–7, 78
problems faced by government (Afrobarometer) 232
sexually transmitted HIV 11
unmet need for family planning 165
Voices of the Poor project 196
Zaric, G. S. 295
ZDV (Zidovudine) program 89, 162–3, 175
zero uptake
and benefit-cost ratios 151
counterfactual 135, 136
simulation results 139
Zimbabwe
alcohol tax 262–3
development indicators 227
health priority survey 230–1
HIV epidemic scale 65–6
HIV incidence/prevalence 12, 13, 19, 301, 324
HIV/AIDS stigma 248–9
key indicators 115–16
life expectancy with/without AIDS 162
male circumcision 23–5
maternal/infant life expectancy 111
problems faced by government (Afrobarometer) 232
unmet need for family planning 165
voluntary HIV testing and counseling uptake at community level 248
Zuma, Jacob 195